Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL

Trial Details

NCT ID
NCT06874946
Phase
PHASE1 / PHASE2
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CD5-targeted CAR-T cells
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • The subject or guardian understands and voluntarily signs the informed consent form (ICF).
  • Male or female, aged 3-70 years at the time of signing the ICF (inclusive).
  • Expected survival of at least 12 weeks.
  • ECOG performance status of 0-2 at the time of ICF signing.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →